TrialBlood2014

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Arthur E Frankel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.